NBTX

Nanobiotix SA Sponsored ADR · NASDAQ

Sector Health Technology
Industry Medical Specialties
Website nanobiotix.com
Employees(FY) 101
ISIN US63009J1079

Performance

+18.15%

1W

+4.7%

1M

-3.77%

3M

+21.69%

6M

-5.22%

YTD

+28.73%

1Y

Profile

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Advanced Technical Analysis

Technical Analysis of NBTX 2024-05-03

Overview:

In analyzing the technical indicators for NBTX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions for informed decisio...

See more ...

Recent News & Updates

2024-04-24 04:40
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results(Globenewswire)
2024-04-17 04:15
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024(Globenewswire)
2024-04-12 22:02
11 Best Nanotechnology Stocks To Invest In(Insidermonkey)
2024-04-10 04:15
Voting Rights and Shares Capital of the Company(Yahoo Finance)
2024-04-02 04:15
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation(Yahoo Finance)
2024-03-06 03:15
Nanobiotix to Present at Upcoming Investor Conferences in March(Globenewswire)
2024-02-13 03:15
Voting Rights and Shares Capital of the Company(Yahoo Finance)
2024-01-31 03:15
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference(Globenewswire)
2024-01-29 22:02
Baillie Gifford Bolsters Stake in Nanobiotix SA(Yahoo Finance)
2024-01-29 03:15
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study(Globenewswire)
2024-01-16 19:00
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors(Globenewswire)
2024-01-11 03:32
Voting Rights and Shares Capital of the Company(Globenewswire)
2023-12-25 13:00
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets(Globenewswire)
2023-12-13 03:15
Voting Rights and Shares Capital of the Company(Yahoo Finance)
2023-12-04 03:22
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation JJDC, Inc.(Globenewswire)
2023-11-13 03:15
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update(Globenewswire)
2023-11-09 03:15
NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023(Globenewswire)
2023-11-08 03:15
Voting Rights and Shares Capital of the Company(Yahoo Finance)
2023-11-07 03:01
NANOBIOTIX Announces Closing of Global Offering(Globenewswire)
2023-11-05 13:00
NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M(Globenewswire)
2023-11-01 22:49
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M(Globenewswire)
2023-11-01 06:32
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant(Globenewswire)
2023-10-22 14:00
NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023(Globenewswire)
2023-10-11 04:27
Voting Rights and Shares Capital of the Company(Yahoo Finance)
2023-10-04 04:30
Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Months(Globenewswire)
2023-09-29 04:15
NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology(Globenewswire)
2023-09-28 04:15
NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer(Globenewswire)
2023-09-26 04:15
NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023(Yahoo Finance)
2023-09-19 04:15
Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023(Yahoo Finance)
2023-09-13 04:15
Voting Rights and Shares Capital of the Company(Yahoo Finance)

Page 1 of 4

previousnext